Skip to content

US · NKTX · BIOTECHNOLOGY

Nkarta, Inc. (NKTX) intrinsic value and stock valuation

$1.14as of 2026-11-21 · Mkt cap 157.4M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nkarta, Inc. DCF and intrinsic value

InvestorsCraft values NKTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NKTX’s statements →

Nkarta, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 nkartatx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-104.08M
20182025
Free cash flow
-$-89.91M
20182025
Total equity
$312.3M-0.6% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-121.21M-$-128.19M-$-131.65M-$-118.95M-$-86.43M
Net income-$-104.08M-$-108.79M-$-117.5M-$-113.84M-$-86.08M
EPSd-$-1.41M-$-1.6M-$-2.4M-$-2.61M-$-2.62M
Operating cash flow-$-88.7M-$-99.7M-$-86.16M-$-57M-$-67.93M
Capital expenditure-$-1.21M-$-4.41M-$-28.15M-$-47.11M-$-5.03M
Free cash flow-$-89.91M-$-104.11M-$-114.31M-$-104.11M-$-72.95M
Total assets$404.2M$501.2M$378.9M$472.9M$273.9M
Total debt$76.4M$80.3M$88.3M$82.9M$12.5M
Net debt$36.8M$52.4M$57.3M$45.4M-$-48.36M
Total equity$312.3M$408M$273.3M$372.2M$251M
Cash and short-term investments$276.3M$267.4M$248.2M$352.1M$238.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$9.19M$0.00$5.87M$0.00$0.00
Gross profit-$-9.19M$0.00-$-5.87M$0.00$0.00
Research and development expenses$90.4M$96.7M$90.9M$90.9M$63.4M
Selling, general and administrative expenses$31.6M$31.5M$34.9M$28.1M$23M
Other expenses-$-9.98M$0.00$0.00$0.00$0.00
Operating expenses$112M$128.2M$125.8M$119M$86.4M
Cost and expenses$121.2M$128.2M$131.7M$119M$86.4M
Interest income$15.5M$19.3M$14.1M$5.59M$370K
Interest expense$0.00$0.00$0.00$5.59M$0.00
Depreciation and amortization$9.19M$9.15M$5.87M$2.64M$1.76M
Ebitda-$-94.89M-$-99.64M-$-120.48M-$-105.61M-$-84.32M
Operating income-$-121.21M-$-128.19M-$-131.65M-$-118.95M-$-86.43M
Total other income/expenses, net$17.1M$19.4M$14.2M$5.12M$350K
Income before tax-$-104.08M-$-108.79M-$-117.5M-$-113.84M-$-86.08M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-104.08M-$-108.79M-$-117.5M-$-113.84M-$-86.08M
Weighted average shares outstanding$74M$67.9M$49M$43.6M$32.9M
Weighted average diluted shares outstanding$74M$67.9M$49M$43.6M$32.9M
Balance sheet
20252024202320222021
Cash and short-term investments$276.3M$267.4M$248.2M$352.1M$238.1M
Net receivables$2M$200K$200K$1.3M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$282.5M$273.3M$253.1M$360.7M$245.8M
Property, plant and equipment, net$101.2M$110.7M$119.3M$107.7M$24.5M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$16.1M$110.4M$2.74M$2.74M$0.00
Total non-current assets$121.7M$227.9M$125.8M$112.3M$28.1M
Total assets$404.2M$501.2M$378.9M$472.9M$273.9M
Accounts payable$2.09M$640K$3.67M$1.76M$1.11M
Short-term debt$6.89M$6.05M$6.07M$4.25M$2.48M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$22.3M$18.9M$23.3M$22.1M$12.9M
Long-term debt$69.5M$74.2M$82.3M$78.7M$9.97M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$69.6M$74.3M$82.3M$78.7M$9.99M
Capital lease obligations$76.4M$80.3M$88.3M$78.7M$12.5M
Total liabilities$91.9M$93.2M$105.6M$100.7M$22.9M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-648.31M-$-544.22M-$-435.43M-$-317.93M-$-204.1M
Accumulated other comprehensive income (loss)$410K$670K$10K-$-680K-$-150K
Total equity$312.3M$408M$273.3M$372.2M$251M
Total investments$252.8M$349.9M$219.9M$317.4M$177.3M
Total debt$76.4M$80.3M$88.3M$82.9M$12.5M
Net debt$36.8M$52.4M$57.3M$45.4M-$-48.36M
Cash flow statement
20252024202320222021
Net income-$-104.08M-$-108.79M-$-117.5M-$-113.84M-$-86.08M
Depreciation and amortization$4.61M$2.24M$5.87M$2.64M$1.76M
Stock-based compensation$8.56M$16.7M$17.2M$16.9M$14.5M
Change in working capital-$-430K-$-12.16M$10.9M$33.7M-$-1.64M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.46M-$-4.47M$4.22M$2.76M$2.79M
Net cash provided by operating activities-$-88.7M-$-99.7M-$-86.16M-$-57M-$-67.93M
Investments in property, plant and equipment-$-1.21M-$-4.41M-$-28.15M-$-47.11M-$-5.03M
Acquisitions, net$0.00$0.00$0.00$140K-$-40K
Net cash used for investing activities$100.3M-$-129.56M$79M-$-184.69M$32.5M
Common stock issued$140K$225.1M$690K$217.2M$1.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$140K$226.1M$690K$219M$1.2M
Net change in cash$11.8M-$-3.17M-$-6.45M-$-22.68M-$-34.19M
Cash at end of period$42.4M$30.6M$33.8M$40.2M$62.9M
Operating cash flow-$-88.7M-$-99.7M-$-86.16M-$-57M-$-67.93M
Capital expenditure-$-1.21M-$-4.41M-$-28.15M-$-47.11M-$-5.03M
Free cash flow-$-89.91M-$-104.11M-$-114.31M-$-104.11M-$-72.95M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nkarta, Inc.

        Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

        CEO
        Paul J. Hastings
        Employees
        108
        Beta
        0.92

        Explore

        Frequently asked questions

        What is the intrinsic value of Nkarta, Inc. (NKTX)?

        InvestorsCraft does not currently publish an intrinsic value for NKTX. How the IC value is calculated.

        Is NKTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for NKTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.